Methods
Study subjects
Needle bleb revision using IRGBR
Data collection
Outcome measures
Statistical analysis
Results
Subject demographic data
With 5-FU Needle Revision Group (n = 30) | Without 5-FU Needle Revision Group (n = 13) | P Value | |
---|---|---|---|
Sex | 0.48* | ||
Men | 15 (51.7%) | 7 (63.6%) | |
Women | 14 (48.3%) | 4 (36.4%) | |
Age at needling (years) | 61.0 ± 16.2 | 63.8 ± 13.5 | 0.68† |
Disease | 0.75* | ||
Primary open-angle glaucoma | 9 (30%) | 5 (38.5%) | |
Secondary glaucoma | 21 (70%) | 8 (61.5%) | |
Neovascular glaucoma | 2 (6.7%) | 0 | |
Exfoliation glaucoma | 6 (20%) | 0 | |
Uveitis | 4 (13.3%) | 4 (30.8%) | |
Others | 9 (30%) | 4 (30.8%) | |
Previous intraocular surgery | 1.4 ± 1.33 | 1.0 ± 1.44 | 0.28† |
Time between previous trabeculectomy and needling (days) | 767.8 ± 898.9 | 890.2 ± 1448.0 | 0.30† |
〜6 months | 14 (46.7%) | 8 (61.5%) | |
6 months 〜 2 years | 5 (16.7%) | 1 (7.7%) | |
2 years 〜 | 11 (36.7%) | 4 (30.8%) | |
IOP pre-needling (mmHg) | 28.9 ± 9.3 | 26.6 ± 9.6 | 0.28† |
Score of glaucoma medications pre-needling (point) | 2.5 ± 2.0 | 2.0 ± 2.1 | 0.38† |
Clinical outcomes of IRGBR
n | With 5-FU Needle Revision Group | n | Without 5-FU Needle Revision Group | P Value | |
---|---|---|---|---|---|
Failure definition 1 | 30 | 13 | |||
1 month | 28 | 93.3 | 5 | 38.5 | |
3 months | 27 | 90.0 | 4 | 30.8 | |
6 months | 24 | 80.0 | 4 | 30.8 | |
12 months | 23 | 76.7 | 3 | 23.1 | |
24 months | 22 | 73.3 | 3 | 23.1 | < 0.0001 |
Failure definition 2 | 30 | 13 | |||
1 month | 28 | 93.3 | 4 | 30.8 | |
3 months | 25 | 83.3 | 1 | 7.7 | |
6 months | 21 | 70.0 | 1 | 7.7 | |
12 months | 20 | 66.7 | 1 | 7.7 | |
24 months | 17 | 56.7 | 1 | 7.7 | < 0.0001 |
IRGBR safety
N (%) | |
---|---|
With 5-FU | 4 (13.3) |
Bleb leak | 3 (10.0) |
Hypotony | 1 (3.3) |
Without 5-FU | 0 |
Risk factors for failure of IRGBR
Failure Definition 1 | Failure Definition 2 | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
Age (years) | ||||||||
≧ 65 | Reference | Reference | Reference | Reference | ||||
<65 | 1.78 (0.67–4.75) | 0.25 | 3.55 (1.06–11.9) | 0.04 | 0.70 (0.32–1.54) | 0.38 | 0.73 (0.30–1.80) | 0.50 |
Sex | ||||||||
Men | Reference | Reference | Reference | Reference | ||||
Women | 1.20 (0.48–3.03) | 0.70 | 1.56 (0.48–5.15) | 0.45 | 1.10 (0.50–2.40) | 0.82 | 1.41 (0.53–3.78) | 0.49 |
Glaucoma | ||||||||
SOAG | 1.10 (0.41–2.94) | 0.85 | 1.13 (0.33–3.92) | 0.85 | 1.45 (0.60–3.47) | 0.41 | 3.43 (1.18–9.95) | 0.02 |
POAG | Reference | Reference | Reference | Reference | ||||
5-FU | ||||||||
Yes | Reference | Reference | Reference | Reference | ||||
No | 5.07 (1.95–13.2) | 0.0009 | 4.90 (1.37–17.5) | 0.01 | 6.29 (2.65–15.0) | < 0.0001 | 6.84 (2.28–20.5) | 0.0006 |
No. previous surgeries | ||||||||
≦ 1 | Reference | Reference | Reference | Reference | ||||
≧ 2 | 0.95 (0.34–2.67) | 0.93 | 2.29 (0.50–10.5) | 0.29 | 0.93 (0.39–2.23) | 0.87 | 1.47 (0.45–4.76) | 0.53 |
No. IOP-lowering medications pre-needling | ||||||||
≦ 2 | Reference | Reference | Reference | Reference | ||||
≧ 3 | 1.20 (0.47–3.07) | 0.70 | 1.21 (0.32–4.53) | 0.78 | 1.10 (0.44–3.30) | 0.85 | 1.38 (0.48–3.99) | 0.55 |
IOP pre-needling (mmHg) | ||||||||
≧ 25 | Reference | Reference | Reference | Reference | ||||
<25 | 1.52 (0.60–3.82) | 0.38 | 1.73 (0.51–5.86) | 0.38 | 1.52 (0.69–3.34) | 0.30 | 1.97 (0.72–5.41) | 0.19 |
IOP 1 week after needling (mmHg) | ||||||||
<10 | Reference | Reference | Reference | Reference | ||||
≧ 10 | 4.63 (1.51–14.2) | 0.007 | 5.54 (1.31–23.4) | 0.02 | 3.19 (1.36–7.50) | 0.008 | 3.99 (1.30–12.3) | 0.02 |
Time between surgery and needling (years) | ||||||||
<1 | Reference | Reference | Reference | Reference | ||||
≧ 1 | 0.61 (0.23–1.63) | 0.33 | 0.93 (0.27–3.20) | 0.91 | 0.66 (0.29–1.49) | 0.31 | 0.87 (0.31–2.40) | 0.79 |